Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypogonadism, Male: early-phase trial registry
6 of 13 indexed Hypogonadism, Male trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 6 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Hypogonadism, Male: 13 US clinical trials tracked, 6 recruiting.
Hypogonadism, Male is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Seattle Institute for Biomedical and Clinical Research, running 2 of these trials.
Enrollment posture brief
Registry condition hypogonadism-male
OPEN 6 | RECR 46% | LATE 4 | EARLY 8 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: B-cell Lymphoma (46% recruiting · 39 trials)
Hypogonadism, Male lists 6 open slots (46% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypogonadism, Male on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypogonadism, Male recruits in line with its size-band peers.
6 of 13 indexed trials (46.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hypogonadism, Male research.
Seattle Institute for Biomedical and Clinical Research accounts for 2 of 13 trials (15.4%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Hypogonadism, Male enrolment sits around 100 participants.
Median target enrolment is 100 among the 13 trials that report a genuine target (sentinel values excluded). 6 of those (46.2%) plan for fewer than 100 participants.
-
Hypogonadism, Male research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
Seattle Institute for Biomedical and Clinical Research
NCT04049331
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Seattle Institute for Biomedical and Clinical Research
NCT04301765
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
Brigham and Women's Hospital
NCT04798469
EndoPAT Device for Endothelial Dysfunction in ED
University of California, Irvine
NCT06720597
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Halozyme Therapeutics
NCT06689085
Testosterone Treatment in Men with Chronic Kidney Disease
St. Louis University
NCT05249634
TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation
University of California, Los Angeles
NCT07287800
Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men
Lipocine
NCT03868059
Vogelxo(R) ABPM Study in Hypogandal Men
Upsher-Smith Laboratories
NCT04558567
A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
University of Miami
NCT04439799
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
GlaxoSmithKline
NCT00398580
Clomid in Men With Low Testosterone With and Without Prior Treatment
Phoenix VA Health Care System
NCT01904734
Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes
Clarus Therapeutics
NCT03973840
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypogonadism, Male records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypogonadism, Male trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypogonadism, Male page
13 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Hypogonadism, Male trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Seattle Institute for Biomedical and Clinical Research sponsors the most Hypogonadism, Male trials on record, review their full trial history before evaluating a specific study. See Seattle Institute for Biomedical and Clinical Research's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypogonadism, Male condition card totals 13 registered trials; most-linked intervention commercially available dutasteride; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.